FN1
Fibronectin
As of the edition of 20 October 2026, FN1 (fibronectin, UniProt P02751) has 5 drugs tested at it and 3 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P02751
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 70
- Disease areas
- Cancer; Eye; Heart and blood vessels; Skin and connective tissue; Nervous system; Digestive system; Hormones; Lungs and airways
- Registered trials of its drugs
- 41
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ocriplasmin | Marketed | Phase 4 | Ended 2024 |
| L19IL2 | Active | Phase 3 | none listed |
| Darleukin | Stopped | Phase 2 | none listed |
| AS-1409 | Went quiet | Phase 1 | none listed |
| L19TNFA | Went quiet | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| ThromboGenics | Route B |
| Antisoma | Route A |
The other 1 company at FN1
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at FN1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.